{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:36:28Z","timestamp":1780554988564,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2002,10,28]],"date-time":"2002-10-28T00:00:00Z","timestamp":1035763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2002,10,28]],"date-time":"2002-10-28T00:00:00Z","timestamp":1035763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2002,11,1]]},"DOI":"10.1038\/sj.leu.2402741","type":"journal-article","created":{"date-parts":[[2002,11,7]],"date-time":"2002-11-07T12:20:43Z","timestamp":1036671643000},"page":"2190-2196","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":702,"title":["Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy"],"prefix":"10.1038","volume":"16","author":[{"given":"A","family":"Hochhaus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kreil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AS","family":"Corbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"La Ros\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MC","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Lahaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Hanfstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Schoch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NCP","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Gschaidmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BJ","family":"Druker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2002,10,28]]},"reference":[{"key":"BF2402741_CR1","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","volume":"340","author":"CL Sawyers","year":"1999","unstructured":"Sawyers CL . Chronic myeloid leukemia N Engl J Med 1999 340: 1330\u20131340","journal-title":"N Engl J Med"},{"key":"BF2402741_CR2","first-page":"751","volume":"10","author":"JV Melo","year":"1996","unstructured":"Melo JV . The molecular biology of chronic myeloid leukaemia Leukemia 1996 10: 751\u2013756","journal-title":"Leukemia"},{"key":"BF2402741_CR3","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Niederwieser D, O'Brien SG, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL . Glivec\u2122 (imatinib mesylate) induces hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase II study Blood 2002 99: 1928\u20131937","journal-title":"Blood"},{"key":"BF2402741_CR4","doi-asserted-by":"publisher","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller C, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MWN, Fischer T, O'Brien SG, Stone R, Gambacorti-Passerini C, Russell N, Reiffers J, Shea T, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ . Glivec\u2122 (imatinib mesylate) induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study Blood 2002 99: 3530\u20133539","journal-title":"Blood"},{"key":"BF2402741_CR5","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 2001 344: 1031\u20131037","journal-title":"N Engl J Med"},{"key":"BF2402741_CR6","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Fernandez Reese S, Ford JM, Capdeville R, Talpaz M . Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 2001 344: 1038\u20131042","journal-title":"N Engl J Med"},{"key":"BF2402741_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMoa011573","volume":"346","author":"H Kantarjian","year":"2002","unstructured":"Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B on behalf of the International STI571 CML Study Group. Imatinib mesylate (Gleevec\u2122) induces hematologic and cytogenetic responses in the majority of patients with chronic myeloid leukemia in chronic phase: results of a phase II study N Engl J Med 2002 346: 645\u2013652","journal-title":"N Engl J Med"},{"key":"BF2402741_CR8","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1182\/blood.V98.13.3864","volume":"98","author":"AJ Tipping","year":"2001","unstructured":"Tipping AJ, Mahon FX, Lagarde V, Goldman JM, Melo JV . Restoration of sensitivity to STI571 in STI571-resistant chronic myeloid leukemia cells Blood 2001 98: 3864\u20133867","journal-title":"Blood"},{"key":"BF2402741_CR9","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","volume":"96","author":"FX Mahon","year":"2000","unstructured":"Mahon FX, Deininger MWN, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV . Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance Blood 2000 96: 1070\u20131079","journal-title":"Blood"},{"key":"BF2402741_CR10","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","volume":"95","author":"E Weisberg","year":"2000","unstructured":"Weisberg E, Griffin JD . Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines Blood 2000 95: 3498\u20133505","journal-title":"Blood"},{"key":"BF2402741_CR11","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","volume":"95","author":"P le Coutre","year":"2000","unstructured":"le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R, Cambarcorti-Passerini C . Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification Blood 2000 95: 1758\u20131766","journal-title":"Blood"},{"key":"BF2402741_CR12","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","volume":"289","author":"T Schindler","year":"2000","unstructured":"Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J . Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase Science 2000 289: 1938\u20131942","journal-title":"Science"},{"key":"BF2402741_CR13","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1126\/science.1062538","volume":"293","author":"ME Gorre","year":"2001","unstructured":"Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL . Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 2001 293: 876\u2013880","journal-title":"Science"},{"key":"BF2402741_CR14","doi-asserted-by":"publisher","first-page":"2163a","DOI":"10.1126\/science.293.5538.2163a","volume":"293","author":"A Hochhaus","year":"2001","unstructured":"Hochhaus A, Kreil S, Corbin A, La Ros\u00e9e P, Lahaye T, Berger U, Cross NCP, Linkesch W, Druker BJ, Hehlmann R . Roots of clinical resistance to STI-571 cancer therapy Science 2001 293: 2163a","journal-title":"Science"},{"key":"BF2402741_CR15","doi-asserted-by":"publisher","first-page":"2163a","DOI":"10.1126\/science.293.5538.2163a","volume":"293","author":"C Barthe","year":"2001","unstructured":"Barthe C, Cony-Makhoul P, Melo JV, Reiffers J, Mahon FX . Roots of clinical resistance to STI-571 cancer therapy Science 2001 293: 2163a","journal-title":"Science"},{"key":"BF2402741_CR16","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","volume":"99","author":"S Branford","year":"2002","unstructured":"Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP . High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance Blood 2002 99: 3472\u20133475","journal-title":"Blood"},{"key":"BF2402741_CR17","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1182\/blood.V99.5.1860","volume":"99","author":"WK Hofmann","year":"2002","unstructured":"Hofmann WK, Jones LC, Lemp NA, de Vos S, Gschaidmeier H, Hoelzer D, Ottmann OG, Koeffler HP . Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation Blood 2002 99: 1860\u20131862","journal-title":"Blood"},{"key":"BF2402741_CR18","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(02)07679-1","volume":"359","author":"N von Bubnoff","year":"2002","unstructured":"von Bubnoff N, Schneller F, Peschel C, Duyster J . BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study Lancet 2002 359: 487\u2013491","journal-title":"Lancet"},{"key":"BF2402741_CR19","first-page":"186","volume":"8","author":"NCP Cross","year":"1994","unstructured":"Cross NCP, Melo JV, Feng L, Goldman JM . An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders Leukemia 1994 8: 186\u2013189","journal-title":"Leukemia"},{"key":"BF2402741_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/sj.leu.2402329","volume":"16","author":"C Schoch","year":"2002","unstructured":"Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T . Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases Leukemia 2002 16: 53\u201359","journal-title":"Leukemia"},{"key":"BF2402741_CR21","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/sj.leu.2401566","volume":"13","author":"M Emig","year":"1999","unstructured":"Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A, Berger U, Hehlmann R, Cross NCP, Hochhaus A . Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR Leukemia 1999 13: 1825\u20131832","journal-title":"Leukemia"},{"key":"BF2402741_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3109\/10428199309047861","volume":"11 (Suppl.\u20091)","author":"NCP Cross","year":"1993","unstructured":"Cross NCP, Feng L, Bungey J, Goldman JM . Minimal residual disease after bone marrow transplant for chronic myeloid leukaemia detected by the polymerase chain reaction Leuk Lymphoma 1993 11 (Suppl.\u20091): 39\u201343","journal-title":"Leuk Lymphoma"},{"key":"BF2402741_CR23","doi-asserted-by":"crossref","first-page":"22925","DOI":"10.1016\/S0021-9258(17)31596-X","volume":"269","author":"T Oda","year":"1994","unstructured":"Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ . Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia J Biol Chem 1994 269: 22925\u201322928","journal-title":"J Biol Chem"},{"key":"BF2402741_CR24","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood.V84.9.2912.2912","volume":"84","author":"GL Nichols","year":"1994","unstructured":"Nichols GL, Raines MA, Vera JC, Lacomis L, Tempst P, Golde DW . Identification of CRKL as the constitutively phosphorylated 39- kD tyrosine phosphoprotein in chronic myelogenous leukemia cells Blood 1994 84: 2912\u20132918","journal-title":"Blood"},{"key":"BF2402741_CR25","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1182\/blood.V84.6.1731.1731","volume":"84","author":"J ten Hoeve","year":"1994","unstructured":"ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J . Tyrosine phosphorylation of CRKL in Philadelphia\u2009+\u2009leukemia Blood 1994 84: 1731\u20131736","journal-title":"Blood"},{"key":"BF2402741_CR26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1182\/blood.V89.1.297","volume":"89","author":"C Heaney","year":"1997","unstructured":"Heaney C, Kolibaba K, Bhat A, Oda T, Ohno S, Fanning S, Druker BJ . Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation Blood 1997 89: 297\u2013306","journal-title":"Blood"},{"key":"BF2402741_CR27","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.1128\/MCB.18.9.5082","volume":"18","author":"K Senechal","year":"1998","unstructured":"Senechal K, Heaney C, Druker B, Sawyers CL . Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells Mol Cell Biol 1998 18: 5082\u20135090","journal-title":"Mol Cell Biol"},{"key":"BF2402741_CR28","doi-asserted-by":"crossref","unstructured":"Corbin AS, Buchdunger E, Pascal F, Druker BJ . Analysis of the structural basis of specificity of STI571 binding to the Abl kinase domain J Biol Chem published 20 June 2002 as 10.1074\/jbc.M111525200","DOI":"10.1074\/jbc.M111525200"},{"key":"BF2402741_CR29","first-page":"100","volume":"56","author":"E Buchdunger","year":"1996","unstructured":"Buchdunger E, Zimmermann J, Mett H, Meyer T, M\u00fcller M, Druker BJ, Lydon NB . Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res 1996 56: 100\u2013104","journal-title":"Cancer Res"},{"key":"BF2402741_CR30","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/0968-0004(90)90281-F","volume":"15","author":"M Saraste","year":"1990","unstructured":"Saraste M, Sibbald PR, Wittinghofer A . The P-loop \u2013 a common motif in ATP- and GTP-binding proteins Trends Biochem Sci 1990 15: 430\u2013434","journal-title":"Trends Biochem Sci"},{"key":"BF2402741_CR31","first-page":"770a","volume":"98 (Supp.\u20091)","author":"NP Shah","year":"2001","unstructured":"Shah NP, Nicoll JM, Gorre ME, Paquette RL, Ford J, Sawyers CL . Resistance to Gleevec: Sequence analysis reveals a spectrum of BCR\/ABL kinase domain mutations in both acquired- and de novo-resistant cases of chronic myelogenous leukemia (CML) in myeloid blast crisis Blood 2001 98 (Supp.\u20091): 770a","journal-title":"Blood"},{"key":"BF2402741_CR32","doi-asserted-by":"publisher","first-page":"8075","DOI":"10.1038\/sj.onc.1205017","volume":"20","author":"K Dorey","year":"2001","unstructured":"Dorey K, Engen JR, Kretzschmar J, Wilm M, Neubauer G, Schindler T, Superti-Furga G . Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase Oncogene 2001 20: 8075\u20138084","journal-title":"Oncogene"},{"key":"BF2402741_CR33","doi-asserted-by":"publisher","first-page":"11283","DOI":"10.1073\/pnas.201398998","volume":"98","author":"P Duesberg","year":"2001","unstructured":"Duesberg P, Stindl R, Hehlmann R . Origin of multidrug resistance in cells with and without multidrug resistance genes: Chromosome reassortment catalyzed by aneuploidy Proc Natl Acad Sci USA 2001 98: 11283\u201311288","journal-title":"Proc Natl Acad Sci USA"},{"key":"BF2402741_CR34","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1053\/beha.2001.0154","volume":"14","author":"A Chase","year":"2001","unstructured":"Chase A, Huntly BJP, Cross NCP . Cytogenetics of chronic myeloid leukemia Best Pract Res Clin Haematol 2001 14: 553\u2013571","journal-title":"Best Pract Res Clin Haematol"},{"key":"BF2402741_CR35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S0140-6736(02)07678-X","volume":"359","author":"WK Hofmann","year":"2002","unstructured":"Hofmann WK, de Vos S, Elashoff D, Gschaidmeier H, Hoelzer D, Koeffler HP, Ottmann OG . Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study Lancet 2002 359: 481\u2013486","journal-title":"Lancet"},{"key":"BF2402741_CR36","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/sj.leu.2402555","volume":"16","author":"P La Ros\u00e9e","year":"2002","unstructured":"La Ros\u00e9e P, O'Dwyer ME, Druker BJ . Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec\/Glivec) in chronic myelogenous leukemia: a translational perspective Leukemia 2002 16: 1213\u20131219","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2402741.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402741","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2402741.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T21:27:08Z","timestamp":1648762028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2402741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10,28]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2002,11,1]]}},"alternative-id":["BF2402741"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2402741","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10,28]]},"assertion":[{"value":"26 June 2002","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2002","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2002","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}